Kidney Cancer Coverage from Every Angle

Does Axitinib Improve Outcomes in Favorable-Risk Patients With Metastatic Kidney Cancer?

By: Kayci Reyer
Posted: Monday, February 4, 2019

The targeted therapy axitinib was found to have a measurable survival benefit in favorable-risk patients with metastatic renal cell carcinoma, according to research published in Targeted Oncology. FavorAx, a phase II study, determined the risk using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

“The encouraging [progression-free survival] and favorable safety profile observed in the FavorAx study support the administration of axitinib in patients with metastatic renal cell carcinoma with favorable IMDC risk and a history of prior sunitinib or pazopanib,” concluded Ilya Tsimafeyeu, MD, of the Kidney Cancer Research Bureau, Moscow, and colleagues.

A total of 21 patients were included in the study, all of whom received axitinib and had clear-cell metastatic renal cell carcinoma, favorable-risk disease, and prior treatment of first-line sunitinib (67%) or pazopanib (33%). The median progression-free survival from first-line therapy was 17 months. The mean participant age was 60 years, and 62% of enrollees were men.

At a median study follow-up of 25 months, the median progression-free survival was 19 months, with a median overall survival not reached. At 18 months, the median overall survival rate was 85.7%. Overall, one patient experienced a complete response. The objective response rate was 33%. A total of 11 patients had changes in axitinib dosage, with 7 undergoing dose escalation and 4 receiving a dose reduction.

In terms of toxicity, 19% of patients experienced grade 3 adverse events. No patient discontinued treatment due to toxicity.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.